Literature DB >> 10741860

HLA-DM and the MHC class II antigen presentation pathway.

P E Jensen1, D A Weber, W P Thayer, X Chen, C T Dao.   

Abstract

The MHC class II antigen processing pathway provides a mechanism to selectively present peptides generated in the endosomal compartments of antigen presenting cells to CD4+ T cells. Transport of newly synthesized class II molecules to the endosomal pathway requires the function of an accessory protein, invariant chain, which contains a region that interacts directly with the class II peptide binding site. Release of invariant chain and peptide loading by class II molecules are facilitated by a second accessory protein, HLA-DM. This MHC-encoded membrane protein catalyzes peptide exchange reactions, influencing the repertoire of peptides that are available for recognition by T cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10741860     DOI: 10.1007/bf02790403

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  66 in total

1.  Irreversible association of peptides with class II MHC molecules in living cells.

Authors:  A Lanzavecchia; P A Reid; C Watts
Journal:  Nature       Date:  1992-05-21       Impact factor: 49.962

2.  Thermal stability comparison of purified empty and peptide-filled forms of a class I MHC molecule.

Authors:  M L Fahnestock; I Tamir; L Narhi; P J Bjorkman
Journal:  Science       Date:  1992-12-04       Impact factor: 47.728

3.  A role for peptide in determining MHC class II structure.

Authors:  S Sadegh-Nasseri; R N Germain
Journal:  Nature       Date:  1991-09-12       Impact factor: 49.962

4.  Mediation by HLA-DM of dissociation of peptides from HLA-DR.

Authors:  V S Sloan; P Cameron; G Porter; M Gammon; M Amaya; E Mellins; D M Zaller
Journal:  Nature       Date:  1995-06-29       Impact factor: 49.962

Review 5.  Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC.

Authors:  P J Fairchild; D C Wraith
Journal:  Immunol Today       Date:  1996-02

6.  Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.

Authors:  P Stumptner; P Benaroch
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

7.  Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP).

Authors:  G Zhong; F Castellino; P Romagnoli; R N Germain
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

8.  Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants.

Authors:  R Cibotti; J M Kanellopoulos; J P Cabaniols; O Halle-Panenko; K Kosmatopoulos; E Sercarz; P Kourilsky
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

9.  Membrane interactions influence the peptide binding behavior of DR1.

Authors:  M A Sherman; H A Runnels; J C Moore; L J Stern; P E Jensen
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

10.  Mapping functional regions in the lumenal domain of the class II-associated invariant chain.

Authors:  M J Bijlmakers; P Benaroch; H L Ploegh
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

View more
  15 in total

Review 1.  The expression of HLA-DO (H2-O) in B lymphocytes.

Authors:  Xinjian Chen; Peter E Jensen
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Role of the major histocompatibility complex class II transmembrane region in antigen presentation and intracellular trafficking.

Authors:  Yelena A Barabanova; Hee-Kap Kang; Jinjong Myoung; Bongsu Kang; Gail A Bishop; Byung S Kim
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

3.  H2-O, a MHC class II-like protein, sets a threshold for B-cell entry into germinal centers.

Authors:  Nicole A Draghi; Lisa K Denzin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-31       Impact factor: 11.205

Review 4.  Understanding the focused CD4 T cell response to antigen and pathogenic organisms.

Authors:  Jason M Weaver; Andrea J Sant
Journal:  Immunol Res       Date:  2009-02-07       Impact factor: 2.829

5.  Exosome-driven antigen transfer for MHC class II presentation facilitated by the receptor binding activity of influenza hemagglutinin.

Authors:  James S Testa; Geraud S Apcher; Joseph D Comber; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2010-11-03       Impact factor: 5.422

Review 6.  Mycobacterium tuberculosis and the intimate discourse of a chronic infection.

Authors:  David G Russell
Journal:  Immunol Rev       Date:  2011-03       Impact factor: 12.988

7.  Human cytomegalovirus US2 endoplasmic reticulum-lumenal domain dictates association with major histocompatibility complex class I in a locus-specific manner.

Authors:  B E Gewurz; E W Wang; D Tortorella; D J Schust; H L Ploegh
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

8.  Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus.

Authors:  Katherine A Richards; Francisco A Chaves; Andrea J Sant
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

9.  Comparative analysis of gingival tissue antigen presentation pathways in ageing and periodontitis.

Authors:  Octavio A Gonzalez; Michael J Novak; Sreenatha Kirakodu; Luis Orraca; Kuey-Chu Chen; Arny Stromberg; Janis Gonzalez-Martinez; Jeffrey L Ebersole
Journal:  J Clin Periodontol       Date:  2014-01-07       Impact factor: 8.728

10.  Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin.

Authors:  Katherine A Richards; Francisco A Chaves; Frederick R Krafcik; David J Topham; Christopher A Lazarski; Andrea J Sant
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.